Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890246) titled 'A Phase 1 Study of IM-1340 in Participants With Advanced Cancer' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Immunome, Inc.
Condition:
Colorectal Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Neuroendocrine Neoplasm
Intervention:
Drug: IM-1340
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 2026
Target Sample Size: 200
To know more, visit https://clinicaltrials.gov/study/NCT07890246
Disclaimer: Curated by...